The Danish Multiple Sclerosis Treatment Register.
The Danish Multiple Sclerosis Treatment Register (DMSTR) serves as a clinical quality register, enabling the health authorities to monitor the quality of the disease-modifying treatment, and it is an important data source for epidemiological research.


METHODS
The DMSTR includes all patients with multiple sclerosis who had been treated with disease-modifying drugs since 1996. At present, more than 8,400 patients have been registered in this database. Data are continuously entered online into a central database from all sites in Denmark at start and at regular visits.


METHODS
Include age, sex, onset year and year of the diagnosis, basic clinical information, and information about treatment, side effects, and relapses.
Notification is done at treatment start, and thereafter at every scheduled clinical visit 3 months after treatment start, and thereafter every 6 months. The longitudinally collected information about the disease activity and side effects made it possible to investigate the clinical efficacy and adverse events of different disease-modifying therapies.


CONCLUSIONS
The database contributed to a certain harmonization of treatment procedures in Denmark and will continue to be a major factor in terms of quality in clinical praxis, research and monitoring of adverse events, and plays an important role in research.
Danish Multiple Sclerosis Registry, Department of Neurology, Rigshospitalet, Copenhagen; Danish Multiple Sclerosis Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Melinda
M
Magyari
Danish Multiple Sclerosis Registry, Department of Neurology, Rigshospitalet, Copenhagen; Department of Clinical Epidemiology, Clinical Institute, University of Aarhus, Aarhus.
Nils
N
Koch-Henriksen
Danish Multiple Sclerosis Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Per Soelberg
PS
Sørensen
disease modifying therapy; epidemiology; immunomodulatory treatment; multiple sclerosis; neutralizing antibodies; observational studies; registry research